Literature DB >> 30084838

Mast Cell Activation and KSHV Infection in Kaposi Sarcoma.

Leona W Ayers1, Arturo Barbachano-Guerrero2, Shane C McAllister3, Julie A Ritchie2, Elizabeth Asiago-Reddy4, Linda C Bartlett4, Ethel Cesarman5, Dongliang Wang6, Rosemary Rochford2, Jeffrey N Martin7, Christine A King8.   

Abstract

Purpose: Kaposi sarcoma (KS) is a vascular tumor initiated by infection of endothelial cells (ECs) with KS-associated herpesvirus (KSHV). KS is dependent on sustained proinflammatory signals provided by intralesional leukocytes and continued infection of new ECs. However, the sources of these cytokines and infectious virus within lesions are not fully understood. Here, mast cells (MCs) are identified as proinflammatory cells within KS lesions that are permissive for, and activated by, infection with KSHV.Experimental Design: Three validated MC lines were used to assess permissivity of MCs to infection with KSHV and to evaluate MCs activation following infection. Biopsies from 31 AIDS-KS cases and 11 AIDS controls were evaluated by IHC for the presence of MCs in KS lesions and assessment of MC activation state and infection with KSHV. Plasma samples from 26 AIDS-KS, 13 classic KS, and 13 healthy adults were evaluated for levels of MC granule contents tryptase and histamine.
Results: In culture, MCs supported latent and lytic KSHV infection, and infection-induced MC degranulation. Within KS lesions, MCs were closely associated with spindle cells. Furthermore, MC activation was extensive within patients with KS, reflected by elevated circulating levels of tryptase and a histamine metabolite. One patient with clinical signs of extensive MC activation was treated with antagonists of MC proinflammatory mediators, which resulted in a rapid and durable regression of AIDS-KS lesions.Conclusions: Using complimentary in vitro and in vivo studies we identify MCs as a potential long-lived reservoir for KSHV and a source of proinflammatory mediators within the KS lesional microenvironment. In addition, we identify MC antagonists as a promising novel therapeutic approach for KS. Clin Cancer Res; 24(20); 5085-97. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30084838      PMCID: PMC6191350          DOI: 10.1158/1078-0432.CCR-18-0873

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  54 in total

1.  Mast cells promote the growth of Hodgkin's lymphoma cell tumor by modifying the tumor microenvironment that can be perturbed by bortezomib.

Authors:  H Mizuno; T Nakayama; Y Miyata; S Saito; S Nishiwaki; N Nakao; K Takeshita; T Naoe
Journal:  Leukemia       Date:  2012-03-20       Impact factor: 11.528

2.  Prostaglandin E2 promotes degranulation-independent release of MCP-1 from mast cells.

Authors:  Takayuki Nakayama; Noriko Mutsuga; Lei Yao; Giovanna Tosato
Journal:  J Leukoc Biol       Date:  2005-11-07       Impact factor: 4.962

3.  Mast cell "densities" in vascular proliferations: a preliminary study of pyogenic granuloma, portwine stain, cavernous hemangioma, cherry angioma, Kaposi's sarcoma, and malignant hemangioendothelioma.

Authors:  K Hagiwara; N M Khaskhely; H Uezato; S Nonaka
Journal:  J Dermatol       Date:  1999-09       Impact factor: 4.005

Review 4.  Mast cells--key effector cells in immune responses.

Authors:  Martin Metz; Marcus Maurer
Journal:  Trends Immunol       Date:  2007-04-02       Impact factor: 16.687

5.  C-Kit (CD117) expression in AIDS-related, classic, and African endemic Kaposi sarcoma.

Authors:  Liron Pantanowitz; Erich J Schwartz; Bruce J Dezube; Sabine Kohler; Ronald F Dorfman; Steven R Tahan
Journal:  Appl Immunohistochem Mol Morphol       Date:  2005-06

6.  Persistent activation of STAT3 by latent Kaposi's sarcoma-associated herpesvirus infection of endothelial cells.

Authors:  Almira S Punjabi; Patrick A Carroll; Lei Chen; Michael Lagunoff
Journal:  J Virol       Date:  2006-12-06       Impact factor: 5.103

7.  Kaposi's sarcoma associated herpes virus (KSHV) induced COX-2: a key factor in latency, inflammation, angiogenesis, cell survival and invasion.

Authors:  Neelam Sharma-Walia; Arun George Paul; Virginie Bottero; Sathish Sadagopan; Mohanan Valiya Veettil; Nagaraj Kerur; Bala Chandran
Journal:  PLoS Pathog       Date:  2010-02-12       Impact factor: 6.823

8.  Mast cells play a protumorigenic role in primary cutaneous lymphoma.

Authors:  Anja Rabenhorst; Max Schlaak; Lukas C Heukamp; Anja Förster; Sebastian Theurich; Michael von Bergwelt-Baildon; Reinhard Büttner; Peter Kurschat; Cornelia Mauch; Axel Roers; Karin Hartmann
Journal:  Blood       Date:  2012-07-26       Impact factor: 22.113

9.  Phenotypic characterization of human skin mast cells by combined staining with toluidine blue and CD antibodies.

Authors:  M Ghannadan; M Baghestanian; F Wimazal; M Eisenmenger; D Latal; G Kargül; S Walchshofer; C Sillaber; K Lechner; P Valent
Journal:  J Invest Dermatol       Date:  1998-10       Impact factor: 8.551

10.  Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 envelope glycoprotein gB induces the integrin-dependent focal adhesion kinase-Src-phosphatidylinositol 3-kinase-rho GTPase signal pathways and cytoskeletal rearrangements.

Authors:  Neelam Sharma-Walia; Pramod P Naranatt; Harinivas H Krishnan; Ling Zeng; Bala Chandran
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

View more
  9 in total

Review 1.  Kaposi Sarcoma, a Trifecta of Pathogenic Mechanisms.

Authors:  Gabriela Rusu-Zota; Oana Mădălina Manole; Cristina Galeș; Elena Porumb-Andrese; Otilia Obadă; Cezar Valentin Mocanu
Journal:  Diagnostics (Basel)       Date:  2022-05-16

2.  Kaposi's Sarcoma-Associated Herpesvirus Infection Induces the Expression of Neuroendocrine Genes in Endothelial Cells.

Authors:  Mohanan Valiya Veettil; Gayathri Krishna; Arunava Roy; Anandita Ghosh; Dipanjan Dutta; Binod Kumar; Sayan Chakraborty; Thoppil Raveendran Anju; Neelam Sharma-Walia; Bala Chandran
Journal:  J Virol       Date:  2020-03-31       Impact factor: 5.103

3.  Association Between Immunoglobulin E Levels and Kaposi Sarcoma in African Adults With Human Immunodeficiency Virus Infection.

Authors:  Helen Byakwaga; Arturo Barbachano-Guerrero; Dongliang Wang; Shane McAllister; Kamal Naphri; Miriam Laker-Oketta; Conrad Muzoora; Peter W Hunt; Jeffrey Martin; Christine A King
Journal:  J Infect Dis       Date:  2021-01-04       Impact factor: 5.226

Review 4.  Use of H-1 Antihistamine in Dermatology: More than Itch and Urticaria Control: A Systematic Review.

Authors:  Chang-Yu Hsieh; Tsen-Fang Tsai
Journal:  Dermatol Ther (Heidelb)       Date:  2021-04-12

Review 5.  Targeting Host Cellular Factors as a Strategy of Therapeutic Intervention for Herpesvirus Infections.

Authors:  Kumari Asha; Neelam Sharma-Walia
Journal:  Front Cell Infect Microbiol       Date:  2021-03-19       Impact factor: 5.293

Review 6.  Cells of the Innate and Adaptive Immune Systems in Kaposi's Sarcoma.

Authors:  Owen Ngalamika; Sody Munsaka
Journal:  J Immunol Res       Date:  2020-11-21       Impact factor: 4.818

7.  Identification of new antiviral agents against Kaposi's sarcoma-associated herpesvirus (KSHV) by high-throughput drug screening reveals the role of histamine-related signaling in promoting viral lytic reactivation.

Authors:  Jungang Chen; Lu Dai; Alana Goldstein; Haiwei Zhang; Wei Tang; J Craig Forrest; Steven R Post; Xulin Chen; Zhiqiang Qin
Journal:  PLoS Pathog       Date:  2019-12-02       Impact factor: 6.823

8.  Extracavitary primary effusion lymphoma recurring with syphilis in an HIV-infected patient.

Authors:  Darakhshan Sohail Ahmed; Marc Poliquin; Louis-André Julien; Jean-Pierre Routy
Journal:  BMJ Case Rep       Date:  2020-11-04

Review 9.  Advances in research on the interaction between inflammation and cancer.

Authors:  Xin-Da Song; Ya-Ni Wang; Ai-Li Zhang; Bin Liu
Journal:  J Int Med Res       Date:  2019-12-29       Impact factor: 1.671

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.